Hers is a telehealth platform offering prescription GLP-1 medications for weight management through remote consultations. This review examines Hers' clinical model, costs, eligibility criteria, and how precision-based approaches like genetic assessment may complement telehealth evaluation.

Mochi and Hers are direct-to-consumer telehealth platforms offering GLP-1 medications, but they differ in provider oversight, genetic assessment, and clinical customization. Biomarker-guided selection and pharmacogenetic insight can inform more personalized treatment pathways.

Hims and Hers are sibling brands run by one parent company, so the real question is why a single platform runs two front doors. This independent PlexusDx review examines the shared infrastructure, the branding split, the common medication pathway, and the biology that infrastructure leaves untouched.

This independent editorial review compares Hers and Brello through the two questions shoppers actually ask: who qualifies at intake, and what the monthly cost really includes. It also explains why GLP-1 pharmacology stays constant across brands and the pathway-level genetic context neither program measures.

This independent editorial review examines how Hers and Noom each build their GLP-1 weight programs, traces where the two telehealth models genuinely diverge in structure and dispensing, and highlights the pathway-level genetic context that neither brand reads before a prescription is ever written for you.

An independent editorial comparison of Hers and Ro, two subscription telehealth brands in the GLP-1 weight-management space. It examines how each program is structured, how their medication and pricing models differ, and the pathway-level genetic variables neither platform maps before prescribing.

Understanding what a telehealth GLP-1 program costs means understanding what drives the price, not chasing a single number. This independent editorial review breaks down how Hers structures its fees, the cash-pay reality, and a cost most programs never account for.

Instead of quoting a single price, this independent editorial review breaks down how Hers is priced: the subscription mechanics, what a monthly charge bundles, the factors that move the total, and how PlexusDx lists its own protocol pricing transparently up front.

This independent editorial review walks through the Hers GLP-1 program, from intake and eligibility to how a prescription is written and filled, the trial evidence behind the compounds, and the genetic groundwork that sits beneath any GLP-1 decision.

Hers accepts HSA/FSA via reimbursement (pay with regular card, submit receipt). PlexusDx accepts HSA/FSA card payment at checkout where your plan permits, with no membership fee — protocols from $129/mo, all 50 states.

Eight month-to-month GLP-1 providers compared against PlexusDx Weight Management Protocols on real annual cost, separate membership fees, intro-price cliffs, and genetic baseline. PlexusDx Microdose at $129/mo flat, Semaglutide Injection $189, Tirzepatide Injection $289, GLP-Squared $289 — all cash-pay, no membership.

Which Wegovy providers actually let you swipe your FSA card at checkout vs. file for reimbursement? NovoCare Pharmacy and LifeMD verified for direct-card payment; Hims, Hers, and Ro are reimbursement-first. Plus what to do when your FSA balance runs out and PlexusDx Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan becomes the flat cash-pay reframe.

MEDVi, Hers, and PlexusDx price GLP-1 care three different ways: MEDVi with an introductory month and a recurring refill rate, Hers with a membership billed apart from branded medication, and PlexusDx with one flat monthly price. This comparison uses each company's own pages as of September 22, 2026 and keeps compounded and branded products separate.

Florida residents can legally start GLP-1 telehealth in days under Statute §456.47. We compare MEDVi, Ro, Walgreens, and the PlexusDx Microdose GLP-1 Protocol from $129/mo — with a genetic baseline option no other Florida provider offers.